DNA Sciences 2025 Q3 Earnings Net Income Plunges 315.4%

DNA Sciences (APDN) reported its fiscal 2025 Q3 earnings on August 15, 2025. The company significantly underperformed expectations, with both revenue and net income plummeting year-over-year. DNA Sciences swung to a loss of $34.00 per share in 2025 Q3 from a profit of $1170.48 per share in the same period last year, marking a 315.4% deterioration in net income.

Revenue
The total revenue of DNA Sciences decreased by 35.6% to $304,393 in 2025 Q3, down from $472,789 in 2024 Q3. Product revenues accounted for $195,262, while service revenues contributed $109,131 to the overall revenue.

Earnings/Net Income
DNA Sciences swung to a loss of $34.00 per share in 2025 Q3 from a profit of $1170.48 per share in 2024 Q3, representing a 102.9% negative change. Meanwhile, the company reported a net loss of $-3.98 million in 2025 Q3, reflecting a 315.4% deterioration from the net income of $1.85 million achieved in 2024 Q3. The Company has sustained losses for 12 years over the corresponding fiscal quarter, highlighting ongoing financial headwinds.

Price Action
The stock price of DNA Sciences has dropped 3.10% during the latest trading day, has dropped 3.78% during the most recent full trading week, and has plummeted 18.27% month-to-date.

Post-Earnings Price Action Review
The strategy of buying DNA Sciences (APDN) shares after a revenue drop quarter-over-quarter on the financial report release date and holding for 30 days resulted in no return over the past three years. The strategy had a CAGR of 0.00% and an excess return of -3.02%, underperforming the benchmark by 3.02%. Additionally, the strategy had a maximum drawdown of 0.00% and volatility of 0.00%, indicating a risk-free but low-return performance.

CEO Commentary
Judy Murrah, Chairperson, President, and CEO of Applied DNA, emphasized the Company’s repositioning as a single business aligned with its core competencies in synthetic DNA and mRNA manufacturing solutions. She highlighted that operations are now “right-sized” and that the Company is actively marketing under the LineaRx brand. Murrah expressed optimism about delivering value to shareholders, underscoring the commercialization of its three technology solutions—LineaDNA, LineaRNAP, and LineaIVT—which are positioned to meet growing demand in biotherapeutics, diagnostics, and mRNA production. The CEO noted that the business is focused on execution, customer engagement, and operational efficiency.

Guidance
The Company expects a further reduction in monthly net cash burn in the quarter ending September 30, 2025, following the implementation of recent restructuring and workforce reduction initiatives. It also anticipates continued cost optimization and operational efficiency as part of its ongoing Corporate Actions. No formal revenue or EPS guidance was provided for future periods, though the Company remains focused on reducing cash burn and advancing commercial adoption of its LineaDNA, LineaRNAP, and LineaIVT platforms.

Additional News
Recent non-earnings related news over the three-week period from August 15, 2025, includes notable updates. In education, the Ministry of Finance announced increased support for special education schools, aiming to strengthen resource allocation. Additionally, multiple universities have decided to extend the standard graduate program duration, with concerns arising over potential dilution of academic rigor. In healthcare, a new public initiative was launched in Shanghai to promote awareness and prevention of childhood obesity, including community-based screening and nutritional counseling programs.